| Literature DB >> 30365823 |
Daniela W Gancz1, Maristela T Cunha2, Claudio Leone3, Joaquim C Rodrigues1, Fabíola V Adde1.
Abstract
OBJECTIVES: The current study sought to evaluate the quality of life of young patients with cystic fibrosis and correlate these results with the clinical parameters indicative of disease severity.Entities:
Mesh:
Year: 2018 PMID: 30365823 PMCID: PMC6172978 DOI: 10.6061/clinics/2017/e427
Source DB: PubMed Journal: Clinics (Sao Paulo) ISSN: 1807-5932 Impact factor: 2.365
Patient demographics and clinical characteristics.
| Mean±SD | 16.4±2.3 |
| Median (range) | 15.7 (14.1-21) |
| Male | 20 (64.5) |
| Female | 11 (35.5) |
| F508del homozygous | 11 (35.5) |
| F508del heterozygous | 11 (35.5) |
| Others | 7 (23) |
| Not investigated | 2 (6) |
| Mean±SD | 4.1±4.3 |
| Median (range) | 3 (0.1-15) |
| 27 (87) | |
| Chronic | 21 (67.7) |
| Intermittent | 5 (16.1) |
| Intermittent/chronic | 23 (74.2) |
| Intermittent/chronic MRSA | 4 (12.9) |
| Intermittent/chronic | 2 (6.4) |
| Mean±SD | 66.9±12.7 |
| Median (range) | 70 (40-85) |
| Mean±SD | 19.3±2.9 |
| Median (range) | 18.4 (14.7-26.3) |
| Mean±SD | 76.9±21.7 |
| Median (range) | 76 (38-145) |
| Mean±SD | 62.9±22.6 |
| Median (range) | 61 (21-121) |
| Pancreatic enzymes | 27 (87) |
| Fat-soluble vitamins | 25 (80.6) |
| Inhaled dornase alfa | 29 (93.5) |
| Inhaled tobramycin | 18 (58) |
| Ursodeoxycholic acid | 11 (35.5) |
| Insulin | 4 (12.9) |
| Metformin | 1 (3.2) |
| Home oxygen therapy | 4 (12.9) |
MRSA, methicillin-resistant Staphylococcus aureus; BMI, body mass index; FVC, forced vital capacity; FEV1, forced expiratory volume in one second.
CFQ-R domains scores.
| Domains | Mean±SD | Median | Minimum | Maximum |
|---|---|---|---|---|
| Body image | 72.8±29 | 77.8 | 11.1 | 100 |
| Emotional functioning | 81±15.4 | 80 | 40 | 100 |
| Role | 86.8±15.2 | 91.7 | 50 | 100 |
| Weight | 63.5±35.9 | 66.7 | 0 | 100 |
| Social | 74±16.4 | 77.8 | 38.9 | 100 |
| Vitality | 78.5±16.8 | 83.3 | 33.3 | 100 |
| Eating disturbances | 83.5±23.3 | 100 | 0 | 100 |
| Digestive symptoms | 93.2±11.7 | 100 | 66.7 | 100 |
| Physical functioning | 75.4±23.7 | 83.3 | 20.8 | 100 |
| Respiratory symptoms | 76.3±11.4 | 77.8 | 44.4 | 94.4 |
| Health perceptions | 77±25.3 | 88.9 | 0 | 100 |
| Treatment burden | 64.1±19.4 | 66.7 | 11.1 | 88.9 |
Figure 1A) The correlation between the weight domain and body mass index (BMI); B) the correlation between the eating domain and BMI; C) the correlation between the physical domain and FEV1; and D) the correlation between the treatment burden domain and FEV1.
Figure 2A) The correlation between the health perceptions domain and the SKS; B) the correlation between the physical functioning domain and the SKS; C) the correlation between the role domain and the SKS.
Figure 3The CFQ-R domain scores for FEV1 values above and below 60% of the predicted value.